파머징(Pharmerging) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Pharmerging Market (Product Type: Pharmaceuticals and Healthcare; and Indication: Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1487567
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 192 Pages
라이선스 & 가격 (부가세 별도)
한글목차
파머징(Pharmerging) 시장- 조사 범위
TMR의 조사 보고서 "파머징(Pharmerging) 세계 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측연도로 삼아 2018년부터 2034년까지 세계 파머징(Pharmerging) 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 파머징(Pharmerging) 시장의 연평균 복합 성장률(CAGR%)도 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 작성되었습니다.
시장 현황
2023년 시장 규모
21억 달러
2034년 시장 가치
71억 달러
CAGR
11.6%
이 보고서는 세계 파머징(Pharmerging) 시장 경쟁 구도에 대해 심층적으로 분석합니다. 세계 제약 시장에서 활동하는 주요 기업들을 식별하고, 각 기업들은 다양한 속성에 따라 프로파일을 작성했습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에서 다루는 세계 제약 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 시장
제4장 시장 개요
서론
시장 개요
시장 역학
시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품 유형/브랜드 분석
주요 M&A
COVID-19 팬데믹의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 제품 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 제품 유형별, 2020-2034년
의약품
브랜드 처방약
제네릭 의약품
브랜드 제네릭 의약품
브랜드 없는 제네릭 의약품
OTC 의약품
헬스케어
의료기기
진단 기기
기타(IT, 기록 관리)
시장의 매력 분석 : 제품 유형별
제7장 세계 시장 분석과 예측 : 적응증별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 적응증별, 2020년-2034년
생활습관병
암 및 자가면역질환
감염증
기타
시장의 매력 분석 : 적응증별
제8장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 유통 채널별, 2020년-2034년
병원
진료소
소매 약국
E-Commerce
드럭스토어
시장의 매력 분석 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 분석 : 지역별
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Abbott Laboratories
Koninklijke Philips N.V.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
AstraZeneca
GlaxoSmithKline plc
Lupin
Tata Consultancy Services Ltd.
Sun Pharmaceutical Industries Ltd.
Huadong Medicine Co., Ltd.
LSH
영문 목차
영문목차
Pharmerging Market - Scope of Report
TMR's report on the global pharmerging market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global pharmerging market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pharmerging market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharmerging market.
Market Snapshot
Market Value in 2023
US$ 2.1 Bn
Market Value in 2034
US$ 7.1 Bn
CAGR
11.6%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pharmerging market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pharmerging market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pharmerging market.
The report delves into the competitive landscape of the global pharmerging market. Key players operating in the global pharmerging market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pharmerging market profiled in this report.
Key Questions Answered in Global pharmerging Market Report:
What is the sales/revenue generated by pharmerging across all regions during the forecast period?
What are the opportunities in the global pharmerging market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Pharmerging Market - Research Objectives and Research Approach
The comprehensive report on the global pharmerging market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global pharmerging market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharmerging market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Pharmerging Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Pharmerging Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product Type /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Pharmerging Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2020-2034
6.3.1. Pharmaceuticals
6.3.1.1. Branded Prescription Drugs
6.3.1.2. Generic Drugs
6.3.1.2.1. Branded Generics
6.3.1.2.2. Unbranded Generics
6.3.1.3. OTC Drugs
6.3.2. Healthcare
6.3.2.1. Medical Devices
6.3.2.2. Diagnostic Instruments
6.3.2.3. Others (IT and Record Management)
6.4. Market Attractiveness Analysis, by Product Type
7. Global Pharmerging Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2020-2034
7.3.1. Lifestyle Diseases
7.3.2. Cancer and Autoimmune Diseases
7.3.3. Infectious Diseases
7.3.4. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Pharmerging Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Retail Pharmacies
8.3.4. E-commerce
8.3.5. Drugs Stores
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Pharmerging Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. Europe
9.2.2. Asia Pacific
9.2.3. Latin America
9.2.4. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. Europe Pharmerging Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2020-2034
10.3.1. Pharmaceuticals
10.3.1.1. Branded Prescription Drugs
10.3.1.2. Generic Drugs
10.3.1.2.1. Branded Generics
10.3.1.2.2. Unbranded Generics
10.3.1.3. OTC Drugs
10.3.2. Healthcare
10.3.2.1. Medical Devices
10.3.2.2. Diagnostic Instruments
10.3.2.3. Others (IT and Record Management)
10.4. Market Value Forecast, by Indication, 2020-2034
10.4.1. Lifestyle Diseases
10.4.2. Cancer and Autoimmune Diseases
10.4.3. Infectious Diseases
10.4.4. Others
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospitals
10.5.2. Clinics
10.5.3. Retail Pharmacies
10.5.4. E-commerce
10.5.5. Drugs Stores
10.6. Market Value Forecast, by Country/Sub-region, 2020-2034
10.6.1. Germany
10.6.2. U.K.
10.6.3. France
10.6.4. Italy
10.6.5. Spain
10.6.6. Rest of Europe
10.7. Market Attractiveness Analysis
10.7.1. By Product Type
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country/Sub-region
11. Asia Pacific Pharmerging Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2020-2034
11.3.1. Pharmaceuticals
11.3.1.1. Branded Prescription Drugs
11.3.1.2. Generic Drugs
11.3.1.2.1. Branded Generics
11.3.1.2.2. Unbranded Generics
11.3.1.3. OTC Drugs
11.3.2. Healthcare
11.3.2.1. Medical Devices
11.3.2.2. Diagnostic Instruments
11.3.2.3. Others (IT and Record Management)
11.4. Market Value Forecast, by Indication, 2020-2034
11.4.1. Lifestyle Diseases
11.4.2. Cancer and Autoimmune Diseases
11.4.3. Infectious Diseases
11.4.4. Others
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Retail Pharmacies
11.5.4. E-commerce
11.5.5. Drugs Stores
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. China
11.6.2. India
11.6.3. Rest of Asia Pacific
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Latin America Pharmerging Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2020-2034
12.3.1. Pharmaceuticals
12.3.1.1. Branded Prescription Drugs
12.3.1.2. Generic Drugs
12.3.1.2.1. Branded Generics
12.3.1.2.2. Unbranded Generics
12.3.1.3. OTC Drugs
12.3.2. Healthcare
12.3.2.1. Medical Devices
12.3.2.2. Diagnostic Instruments
12.3.2.3. Others (IT and Record Management)
12.4. Market Value Forecast, by Indication, 2020-2034
12.4.1. Lifestyle Diseases
12.4.2. Cancer and Autoimmune Diseases
12.4.3. Infectious Diseases
12.4.4. Others
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Retail Pharmacies
12.5.4. E-commerce
12.5.5. Drugs Stores
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. Brazil
12.6.2. Mexico
12.6.3. Rest of Latin America
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Middle East & Africa Pharmerging Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2020-2034
13.3.1. Pharmaceuticals
13.3.1.1. Branded Prescription Drugs
13.3.1.2. Generic Drugs
13.3.1.2.1. Branded Generics
13.3.1.2.2. Unbranded Generics
13.3.1.3. OTC Drugs
13.3.2. Healthcare
13.3.2.1. Medical Devices
13.3.2.2. Diagnostic Instruments
13.3.2.3. Others (IT and Record Management)
13.4. Market Value Forecast, by Indication, 2020-2034
13.4.1. Lifestyle Diseases
13.4.2. Cancer and Autoimmune Diseases
13.4.3. Infectious Diseases
13.4.4. Others
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Retail Pharmacies
13.5.4. E-commerce
13.5.5. Drugs Stores
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. GCC Countries
13.6.2. South Africa
13.6.3. Rest of Middle East & Africa
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
